President Trump considers imposing retaliatory economic sanctions on Chinese products.

Peter Prince

2018-01-10 08:40:00 Wed ET

President Trump considers imposing retaliatory economic sanctions on Chinese products and services in direct response to China's theft and infringement of U.S. intellectual property. Trump's retaliatory trade sanctions may involve tariffs, quotas, embargoes, and other restrictions on China's investments in U.S. companies. This punitive penalty arises as part of a recent Trade Act Section 301 probe into China's recent regulations that induce U.S. multinational corporations to establish onshore IT data centers. These regulations force unfair intellectual property and technology transfer from these U.S. multinational corporations to their Chinese counterparts. Without such technology transfer, the use and implementation of U.S. patents and trademarks would otherwise involve egregious infringement at the expense of U.S. firms and other innovators.

Recent empirical evidence suggests that this unfair technology transfer may be the root cause of both billions of dollar losses in corporate revenue as well as millions of job losses in America. In addition to intellectual property theft and infringement, the Trump administration also accuses China of currency manipulation. Over the years, China has been accumulating substantial dollar reserves in the form of U.S. Treasury bonds for better renminbi devaluation. This deliberate devaluation leads to more competitive Chinese export prices and thus better low-cost product sales abroad. The Trump administration needs to consider retaliatory trade sanctions on China in order to eradicate trade deficits with better fiscal discipline.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Amazon CEO Jeff Bezos admits the fact that antitrust scrutiny remains a primary imminent threat to his e-commerce business empire.

John Fourier

2019-04-17 11:34:00 Wednesday ET

Amazon CEO Jeff Bezos admits the fact that antitrust scrutiny remains a primary imminent threat to his e-commerce business empire.

Amazon CEO Jeff Bezos admits the fact that antitrust scrutiny remains a primary imminent threat to his e-commerce business empire. In his annual letter to A

+See More

With prescient clairvoyance, Bill Gates predicted the recent rise of Facebook and Netflix.

Monica McNeil

2017-02-07 07:47:00 Tuesday ET

With prescient clairvoyance, Bill Gates predicted the recent rise of Facebook and Netflix.

With prescient clairvoyance, Bill Gates predicted the recent sustainable rise of Netflix and Facebook during a Playboy interview back in 1994. He said th

+See More

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Dan Rochefort

2018-05-10 07:37:00 Thursday ET

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions.

Top money managers George Soros and Warren Buffett reveal their current stock and bond positions in their recent corporate disclosures as of mid-2018. Georg

+See More

President Trump's current trade policies appear like the Reagan administration's protectionist trade policies back in the 1980s.

Apple Boston

2018-07-03 11:42:00 Tuesday ET

President Trump's current trade policies appear like the Reagan administration's protectionist trade policies back in the 1980s.

President Trump's current trade policies appear like the Reagan administration's protectionist trade policies back in the 1980s. In comparison to th

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Agile lean enterprises strive to design radical business models to remain competitive in the face of nimble startups and megatrends.

Joseph Corr

2020-10-13 08:27:00 Tuesday ET

Agile lean enterprises strive to design radical business models to remain competitive in the face of nimble startups and megatrends.

Agile lean enterprises strive to design radical business models to remain competitive in the face of nimble startups and megatrends. Carsten Linz, Gunter

+See More